QR-Code

Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma
with Acquired High-level HER2 Amplification: A Case Report

Trastuzumab deruxtecan is a newly developed antibody-drug conjugate (ADC) designed to overcome human epidermal growth factor receptor 2 (HER2) aberrations. Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a manageable safety profile in previously treated non-small ce...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Xiaoxiao GE, Hefeng CHEN, Shaohua CUI
Format: Artigo
Sprache:Chinês
Veröffentlicht: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2026-03-01
Schriftenreihe:Chinese Journal of Lung Cancer
Schlagworte:
lung neoplasms
trastuzumab deruxtecan
her2 amplification
acquired resistance
case report
Online-Zugang:http://dx.doi.org/10.3779/j.issn.1009-3419.2026.104.01
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge